Dr. César López-Camacho
Vaccine development for infectious diseases and immunopathogenesis
César López-Camacho holds a PhD in Molecular Biology from the University of Manchester, United Kingdom, and has held four postdoctoral positions in molecular biology, fidelity of gene expression, and vaccinology at UMASS Medical School-USA, University of Vermont College of Medicine-USA and the Jenner Institute at University of Oxford, respectively. He is currently a Senior Postdoctoral Researcher working with Prof. Gavin Screaton at the Wellcome Centre for Human Genetics, here at Oxford.
Since the COVID-19 outbreak, his current scientific activity encompasses the design and protein production of SARS-CoV-2 antigens to be utilised as diagnostic tools and for coronavirus research applications. He is part of both the COVID-19 Outbreak Expert Database for the UK parliament, and the National COVID Testing Scientific Advisory Panel.
In the pre-COVID era, his main research aims are the immunopathogenesis of Dengue virus and vaccine development of novel antigen candidates, to induce specific anti-flavivirus antibody responses against functional and conformational epitopes.
Doctor López-Camacho joined the Jenner Institute in 2014 as a postdoctoral researcher in Reyes-Sandoval’s group and worked on vaccine development for several arboviruses (Zika, Dengue, Chikungunya and Mayaro viruses). During this time he published 14 papers, both as first author and as co-author, in relation to arboviral, parasitic (malaria and chagas disease) and Papillomavirus vaccine developments.
In terms of intellectual property activities, he is an inventor and collaborator in vaccine-related Patents.
López-Camacho C. et al, (2018), Nature Communications, 9
Kroon Campos R. et al, (2019), Pathogens, 8, 231 - 231
Slon-Campos JL. et al, (2019), Nature immunology, 20, 1291 - 1298
Kim YC. et al, (2019), Viruses, 11, 407 - 407